Genesee Valley Trust Co. increased its stake in Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 2.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,005 shares of the biopharmaceutical company’s stock after buying an additional 61 shares during the period. Genesee Valley Trust Co.’s holdings in Regeneron Pharmaceuticals were worth $1,049,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. BlackRock Institutional Trust Company N.A. increased its stake in shares of Regeneron Pharmaceuticals by 0.7% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,961,289 shares of the biopharmaceutical company’s stock valued at $706,927,000 after buying an additional 13,215 shares during the period. BlackRock Fund Advisors increased its stake in shares of Regeneron Pharmaceuticals by 5.4% in the first quarter. BlackRock Fund Advisors now owns 2,208,677 shares of the biopharmaceutical company’s stock valued at $796,096,000 after buying an additional 113,864 shares during the period. Franklin Resources Inc. increased its stake in shares of Regeneron Pharmaceuticals by 4.8% in the first quarter. Franklin Resources Inc. now owns 667,283 shares of the biopharmaceutical company’s stock valued at $240,516,000 after buying an additional 30,562 shares during the period. Pacad Investment Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 194.1% in the first quarter. Pacad Investment Ltd. now owns 8,400 shares of the biopharmaceutical company’s stock valued at $3,028,000 after buying an additional 5,544 shares during the period. Finally, Parametrica Management Ltd bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $404,000. 68.16% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded up 0.85% during trading on Tuesday, hitting $406.24. The stock had a trading volume of 626,928 shares. Regeneron Pharmaceuticals Inc. has a 52-week low of $329.09 and a 52-week high of $592.59. The company has a 50-day moving average price of $409.49 and a 200-day moving average price of $389.48. The company has a market cap of $42.51 billion, a price-to-earnings ratio of 63.38 and a beta of 1.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.17. The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.24 billion. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The firm’s quarterly revenue was up 21.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.89 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals Inc. will post $10.93 EPS for the current year.

Several brokerages have recently commented on REGN. Vetr raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.09 price objective for the company in a research note on Tuesday, August 2nd. Canaccord Genuity reissued a “hold” rating and issued a $450.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. Robert W. Baird downgraded Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $505.00 to $448.00 in a research note on Friday, August 5th. Cowen and Company reissued a “hold” rating and issued a $430.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. Finally, Roth Capital reissued a “buy” rating and issued a $520.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $470.91.

In related news, Director Joseph L. Goldstein sold 2,125 shares of the company’s stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $425.00, for a total value of $903,125.00. Following the transaction, the director now directly owns 15,125 shares of the company’s stock, valued at approximately $6,428,125. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.40% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN).

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.